Good morning, Boston. Here are the five things you need to know in Boston business news to start your day.
The FDA’s decision to expand approval for a Cambridge company’s controversial gene therapy could signal a changing approach to how the federal agency deals with medicines for deadly, rare diseases.
Also from Hannah, in the cover story of the latest Weekly Edition, she reports that rising drug costs have stirred a national conversation on affordability. As more gene therapies are approved…
Source link